Analyst Ratings For NASDAQ:RIGL – Rigel Pharmaceuticals (NASDAQ:RIGL)
Today, HC Wainwright lowered its price target on NASDAQ:RIGL – Rigel Pharmaceuticals (NASDAQ:RIGL) to $7.50 per share.
Some recent analyst ratings include
- 8/3/2016-JPMorgan Chase Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:RIGL – Rigel Pharmaceuticals (NASDAQ:RIGL)
NASDAQ:RIGL – Rigel Pharmaceuticals (NASDAQ:RIGL) has insider ownership of 5.38% and institutional ownership of 92.11%.
- On 4/20/2018 Anne-Marie Duliege, EVP, sold 5,000 with an average share price of $4.11 per share and the total transaction amounting to $20,550.00.
- On 11/3/2017 Ryan D Maynard, CFO, sold 100,000 with an average share price of $3.90 per share and the total transaction amounting to $390,000.00.
- On 7/5/2017 Anne-Marie Duliege, Insider, sold 5,000 with an average share price of $2.69 per share and the total transaction amounting to $13,450.00.
- On 8/30/2016 Donald G Payan, EVP, sold 5,303 with an average share price of $4.00 per share and the total transaction amounting to $21,212.00.
- On 4/1/2015 Donald G Payan, EVP, sold 10,000 with an average share price of $3.75 per share and the total transaction amounting to $37,500.00.
- On 12/18/2014 Dolly Vance, EVP, sold 1,000 with an average share price of $2.22 per share and the total transaction amounting to $2,220.00.
- On 9/3/2014 Donald G Payan, EVP, sold 20,000 with an average share price of $2.56 per share and the total transaction amounting to $51,200.00.
Recent Trading Activity for NASDAQ:RIGL – Rigel Pharmaceuticals (NASDAQ:RIGL)
Shares of NASDAQ:RIGL – Rigel Pharmaceuticals closed the previous trading session at 3.94 up +0.24 6.57% with 1030458 shares trading hands.